Atos Unveils Biometric Identity-as-a-Service Solution for the Enterprise

Atos has unveiled a new identity and access management (IAM) solution for the enterprise. The Evidian IDaaS (Identity-as-a-Service) platform can be used for physical and digital access control, and is available through the cloud on a subscription pricing model.

Evidian IDaaS supports biometric and multi-factor authentication, and is compliant with FIDO2 standards and the latest PSD2 and GDPR regulations. The solution is based on the Google Cloud Platform. It can be used to secure customer-facing applications, or to grant employees access to various online resources or physical locations.

Evidian enables passwordless authentication and was designed in accordance with Zero Trust security principles. Atos indicated that the solution will give enterprise customers an easy way to manage and grant access to large numbers of digital identities.     

“Recent paradigm shifts, which include identities being the number one attack vector, place IAM at the heart of cybersecurity strategies,” said Atos Identity and Access Management Head Sébastien Brachet. “With our new solution, we give our clients the power to manage their IT environment, facilitating day-to-day management and increasing overall security.” 

Identity and access management has become particularly important in the past few weeks, as more organizations have transitioned to a remote work environment in response to the COVID-19 pandemic. There has also been an increase in social engineering attacks as fraudsters look to take advantage of the disruption.

Atos itself recently signed a three-year contract with AENA. The company will provide AENA with biometric recognition systems – as well as better analytics technology and AI and IoT capabilities – for its numerous airports in Spain and Latin America.

Atos was originally supposed to coordinate a face-based access control system for the 2020 Olympic Games in Tokyo. However, those games have been postponed until 2021 due to public health concerns related to the novel coronavirus. 

–

April 15, 2020 – by Eric Weiss